MediGene AG · LS:A40ESG
MediGene — H1 2013 Earnings Presentation
15 slides from MediGene's earnings presentation, Aug 9, 2013
Slide 1: Analyst conference call: Results for the first 6 months of 2013
Analyst conference call Results for the first 6 months of 2013 9 August 2013 Dr. Frank Mathias, CEO Peter Llewellyn-Davies, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Major events since the beginning of 2013
Major events since the beginning of 2013 Veregen®: In-market sales increased by 48% Market launch in Serbia and the Netherlands Market approval in the Czech Republic and Taiwan Partnership agreements concluded for marketing Veregen® in Asia, Australia, New Zealand and Italy Inclusion of Veregen® in
Slide 4: Major events since the beginning of 2013
Major events since the beginning of 2013 RhuDex®: Expansion of clinical trial plan for Phase II in primary biliary cirrhosis (PBC) AAVLP: Preliminary preclinical data on successful protection against several major HPV virus subtypes Corporate: SynCore as new strategic core investor AGM approves redu
Slide 5: Financial Report 6M 2013
Financial Report 6M 2013 Peter Llewellyn-Davies, CFO 5
Slide 6: Financial highlights for 6M 2013
Financial highlights for 6M 2013 6M financials within guidance Revenue from royalties on Veregen® increased by 46% Increase of in-market sales by 48% up to € 8.0 m Growing market demand Without 2012 one-time effect (recognition of reimbursement €0.4m): Total revenue increased by 10% to €3.2 m Loss o
Slide 7: Steadily growing Veregen sales
Steadily growing Veregen® sales In € m *without one-time effect Veregen® In-market sales Total Veregen® revenue Total revenue 3.3 13% 1.9 48% 10% 3.2 8.0 1.7 2.9* 5.4 6M 2012 6M 2013 6M 2012 6M 2013 6M 2012 6M 2013 Revenue (in € k) 6M 2012 6M 2013 Change Veregen® Royalties 849 1,243 46% Revenue from
Slide 8: Further reduction of operating expenses
Further reduction of operating expenses In € m R&D expenses SG&A expenses -5% -7% 3.6 3.4 3.9 3.6 6M 2012 6M 2013 6M 2012 6M 2013 R&D costs reduced by 5% SG&A costs reduced by 7% Lower clinical trial Higher selling expenses due to expenses higher marketing costs for Veregen® Increased preclinical de
Slide 9: Improvement on EBITDA (without one-time effects)
Improvement on EBITDA (without one-time effects) In € m EBITDA 6-Months net result 0.8 2.2 -4.3 -5.7 -4.6* * 6M 2012 6M 2013 6M 2012 6M 2013 *without one-time effect Reduction of EBITDA loss of 6% year-on-year (without one-time effects) Difference between 6M 2012 and 2013 comprises Income from compe
Slide 10: Cash position of €15.0 m
Cash position of €15.0 m In € m 20.1 <-0.1 7.5 <-0.1 2.4 15.0 Cash as of 1 Jan Cash flow from Cash flow from Cash flow from Foreign exchange Cash as of 30 June 2013 operating activities investing activities financing activities differences 2013 Cash flow from financing activities comprises payment o
Slide 11: Financial guidance for 2013 improved
Financial guidance for 2013 improved Previous Updated 2012 Guidance 2013 Guidance 2013 (22.03.2013) (09.08.2013) Total revenue €6.3 m €7 - 8 m €8 - 9 m thereof Veregen® €3.4 m €4.5 - 5.5 m €4.5 - 5.5 m thereof non-cash income €1.9 m €2.5 m €2.5 m EBITDA loss €9.4 m* €9 - 11 m €8 - 10 m *from continu
Slide 12: Changes to corporate structure
Changes to corporate structure Ordinary reduction of share Shareholder structure* capital from approved at AGM 2013 with majority of 93% Freefloat (< 3%) 83,50% Reduction from 39,488,556 to 9,872,139 shares by ratio of 4:1 Santo Holding 4,32% Measure will not affect value of Advent the company 6,09%
Slide 13: Outlook
Outlook Veregen® Revenue growth in significant double-digit percent range Approvals and market launches in additional countries Additional marketing and partnership agreements Market authorization applications for remaining European countries to start mid 2014 EndoTAG®-1 Start phase III trial planne
Slide 14: Questions & Answers
medigene Questions & Answers
Slide 15: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg/Martinsried Planegg / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG, Prime Standard)